UC Santa Cruz Researchers Spotlight Overlooked Peptide P3 as Potential Alzheimer’s Culprit

For decades, Alzheimer’s research has centered on amyloid beta, driving billions of dollars in drug development that largely failed to alter disease progression. A new study from UC Santa Cruz suggests that a different peptide—P3—may have been ignored. Once considered harmless, P3 can aggregate into protein clumps faster than amyloid beta and may damage brain cells. The findings imply that the focus on amyloid beta alone might have missed a key player in the disease’s pathology. If P3’s role is confirmed, it could shift therapeutic strategies toward targeting this peptide, potentially opening new avenues for treatment.